Search | Clinical Trials Finder

Conditions: Arginine Vasopressin Deficiency, Oxytocin Deficiency, Pediatric Disease, Hypopituitarism
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions: GSK189075, Brevicon; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ethinyl Estradiol and Norethindrone, Healthy Volunteers
Interventions: isavuconazole, Oral Contraceptive (ethinyl estradiol / norethindrone); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 50 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: BMS-986166, Oral contraceptive; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Contraception
Interventions: Norethindrone/ethinyl estradiol; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 63
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 53 more

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, Oral contraceptive (Brevicon); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Solid Cancers
Interventions: Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Houston, Texas

Conditions: Contraception, Ovulation
Interventions: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate, Norethindrone; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy Subjects
Interventions: lemborexant, Loestrin, famotidine, fluconazole; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Arginine Vasopressin Deficiency, Oxytocin Deficiency
Interventions: Norethindrone Acetate-Ethinyl Estradiol; Drug
Lead sponsor: Elizabeth Austen Lawson; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Participants
Interventions: BMS-986256, Loestrin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cypress, California

Conditions: Cystic Fibrosis (CF)
Interventions: Loestrin (norethindrone acetate and ethinyl estradiol); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Prevention of Pregnancy
Interventions: Norethindrone Acetate/Ethinyl Estradiol 24 Days, Norethindrone Acetate /Ethinyl Estradiol 21 Days; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 938 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 34
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chico, California + 28 more

Conditions: Healthy Female Volunteers
Interventions: BMS-986196, Loestrin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: Oral Contraceptive
Interventions: Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon Fe®; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions: SexHealth II, Contraceptive; Behavioral · Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Oral Contraceptive, Loestrin 1.5/30; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Ortho-Novum 777; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 15
States / cities: Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 11 more

Conditions: Healthy Volunteers
Interventions: Microgestin®, Levothyroxine, Glyburide, Digoxin, IW-3718; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Norethindrone/Ethinyl Estradiol, FEMCON® Fe; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Solid Tumors
Interventions: Trametinib, Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 59 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Detroit, Michigan • Oklahoma City, Oklahoma

Conditions: HIV Infections
Interventions: VH4524184, Loestrin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pelvic Pain, Headaches, Emotional
Interventions: loestrin 24/4 vs loestrin 1/20, loestrin 1/20; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Temple, Texas

Conditions: HIV Infections, Pregnancy
Interventions: Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more

Search by objective public record fields.

Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease

A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers

Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone

A Study to Characterize the Drug Levels of an Oral Contraceptive With and Without BMS-986166 in Healthy Female Participants of Childbearing Potential

Study of Safety and Efficacy of an Oral Contraceptive

An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .

A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Ovulation Incidence in Oral Contraceptive Users

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Identifying Oxytocin Deficiency in Adults With Pituitary Disease

A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants

Gender Disparity and Hormones in Cystic Fibrosis

Study of Safety and Efficacy of an Oral Contraceptive

A Study to Evaluate the Drug-drug Interaction of BMS-986196 With Oral Contraceptives in Healthy Female Participants

Oral Contraceptive (OC) Progestin Dose and Breast Proliferation

Inpatient Adolescent Contraception

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Safety of Estrogens in Lupus: Birth Control Pills

Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers

Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women